Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com//news-release/2023/10/05/2755336/0/en/Aerami-Therapeutics-to-Present-Data-Supporting-AER-901-Dosing-Regimen-at-CHEST-2023.html
https://www.globenewswire.com//news-release/2023/09/12/2741811/0/en/Aerami-Therapeutics-Announces-Presentation-of-Phase-1-Clinical-Trial-Data-for-Lead-Program-AER-901-at-the-2023-European-Respiratory-Society-ERS-International-Congress.html
https://www.contractpharma.com/contents/view_breaking-news/2023-06-02/aerami-therapeutics-expands-management-team/?widget=listSection
https://www.globenewswire.com/news-release/2023/06/01/2680278/0/en/Aerami-Therapeutics-Appoints-Joshua-Ziel-as-COO-and-Interim-CEO-and-Expands-Management-Team-as-Lead-Asset-AER-901-inhaled-imatinib-Advances-Toward-Phase-2-in-Pulmonary-Hypertension.html
https://www.globenewswire.com/news-release/2023/05/24/2675269/0/en/Aerami-Therapeutics-Announces-Pharmacokinetic-Data-Demonstrating-the-Potential-of-AER-901-Inhaled-Imatinib-to-Achieve-Therapeutic-Levels-at-Low-Inhaled-Doses-for-Treatment-of-Pulmo.html
https://www.globenewswire.com/news-release/2023/05/11/2666641/0/en/Aerami-Therapeutics-to-Present-Pharmacokinetic-Data-Supporting-AER-901-Inhaled-Imatinib-for-Pulmonary-Hypertension-at-the-2023-American-Thoracic-Society-ATS-International-Conferenc.html
https://www.globenewswire.com/news-release/2023/05/05/2662418/0/en/Aerami-Therapeutics-Mourns-the-Sudden-Loss-of-Chief-Executive-Officer-Lisa-Ya%C3%B1ez.html
https://endpts.com/aerami-therapeutics-ceo-lisa-yanez-passes-away-chair-to-lead-heart-disease-biotech/
https://www.globenewswire.com/news-release/2023/04/03/2639642/0/en/Aerami-Therapeutics-to-Host-Virtual-Investor-Day-with-Leading-Experts-in-Pulmonary-Hypertension-as-AER-901-Inhaled-Imatinib-Advances-Toward-Phase-2.html
https://www.globenewswire.com/news-release/2023/02/23/2614380/0/en/Aerami-Therapeutics-Announces-Expansion-of-the-AER-901-inhaled-imatinib-Development-Program-in-Pulmonary-Hypertension-Supported-by-Phase-1-Clinical-Trial-Data-and-Continued-Progres.html